Atlantic Union Bankshares Corp Acquires Shares of 17,541 iShares Biotechnology ETF $IBB

Atlantic Union Bankshares Corp bought a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 17,541 shares of the financial services provider’s stock, valued at approximately $2,219,000.

Several other hedge funds have also modified their holdings of the stock. Ramirez Asset Management Inc. bought a new position in iShares Biotechnology ETF in the 1st quarter worth approximately $26,000. Berkshire Money Management Inc. acquired a new stake in shares of iShares Biotechnology ETF in the 2nd quarter valued at $28,000. Financial Gravity Asset Management Inc. acquired a new stake in shares of iShares Biotechnology ETF in the 1st quarter valued at $30,000. Woodside Wealth Management LLC bought a new stake in shares of iShares Biotechnology ETF during the first quarter worth $31,000. Finally, Harbor Asset Planning Inc. acquired a new position in shares of iShares Biotechnology ETF during the second quarter valued at $31,000. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Trading Down 0.4%

iShares Biotechnology ETF stock opened at $157.72 on Friday. The business’s 50-day simple moving average is $148.73 and its 200 day simple moving average is $135.55. iShares Biotechnology ETF has a 12-month low of $107.43 and a 12-month high of $159.79.

iShares Biotechnology ETF Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 19th. Shareholders of record on Tuesday, September 16th were paid a $0.0828 dividend. The ex-dividend date of this dividend was Tuesday, September 16th. This represents a $0.33 annualized dividend and a yield of 0.2%.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.